× HOME INDUSTRIES INSIGHTS ABOUT CONTACT

Netherlands Medical Hemostatic Agents Market Size and Share 2026 to 2033

Netherlands Medical Hemostatic Agents Market Size, Share, Trends and Growth, by Segments Product Type, Application, End-User by 2026-2033

ID : MRU_431403 | Date : Oct 2026 | Pages : 246 | Region : Europe › Netherlands | Base Year : 2025 | Forecast : 2026-2033

Netherlands Medical Hemostatic Agents Market - Key Highlights

  • The Netherlands Medical Hemostatic Agents market is assessed at USD 68.1 Million in 2026 and is projected to reach USD 106.38 Million by 2033, the end of the forecast period.
  • The Netherlands Medical Hemostatic Agents market is anticipated to expand at a CAGR of 6.58% between 2026 and 2033.
  • On a geographic basis, the USA accounted for the largest share of 42.3% of the Global Medical Hemostatic Agents market in 2025.
  • The Thrombin-Based segment dominated with a revenue share of 34.6% in 2025 by Product Type, backed by routine use in cardiac and general surgery.
  • Netherlands Medical Hemostatic Agents market participants stand to gain from technological development, strategic investments, capacity expansion, and product innovation, which are creating additional growth opportunities.
  • South Korea is expected to record the highest CAGR of 9.7% during the forecast period 2026–2033.
  • Within the Application category, the Trauma segment is anticipated to record the highest CAGR of 8.9% from 2026 to 2033.
  • The market is anticipated to witness sustained growth over the period to 2033 as geographic penetration, technological advancement, application expansion, and demand increase.

Netherlands Medical Hemostatic Agents Market Size & Forecast

Netherlands Medical Hemostatic Agents Market Size, Value & Y-o-Y Growth Chart 2019-2033

Netherlands Medical Hemostatic Agents Market - Frequently Asked Questions

How are Medical Hemostatic Agents sold and distributed in the Netherlands?

Medical Hemostatic Agents in the Netherlands reach buyers mainly through hospital group purchasing, specialist surgical distributors and direct sales teams from manufacturers. Dutch hospitals concentrate purchasing through regional purchasing cooperatives, so suppliers usually need a local distributor or a framework agreement to get onto the shelf. ASCs tend to buy through the same distributors at smaller volumes.

What are the biggest opportunities in the Netherlands Medical Hemostatic Agents market?

The biggest opportunities in the Netherlands Medical Hemostatic Agents market lie in bio-derived and synthetic combination agents, where surgeons want faster clot formation with fewer units used per procedure. Aging population and complex surgeries drive demand, so suppliers that can show clinical and cost benefits in cardiovascular and general surgery stand to gain. Product innovation and capacity expansion give entrants room to differentiate.

What is the Netherlands share of the European Medical Hemostatic Agents market?

The Netherlands accounts for 4.6% of the European Medical Hemostatic Agents market in 2026, when Europe is valued at USD 1.5 Billion. That places the country sixth of the seven countries covered in Europe by 2033 market size. Germany, the UK, France, Italy and Spain all sit ahead of it, so the Netherlands is a mid-sized market with limited scale.

Which regulations affect Medical Hemostatic Agents in the Netherlands?

Medical Hemostatic Agents sold in the Netherlands must carry CE marking under EU medical device rules, with Dutch authorities supervising post-market surveillance and traceability. High cost and complex regulations restrain growth because smaller suppliers struggle with the documentation and clinical evidence needed for approval. Companies should plan for notified body review timelines before setting launch dates.

How do Dutch hospitals choose between Medical Hemostatic Agents suppliers?

Dutch hospitals choose Medical Hemostatic Agents suppliers on clinical evidence, price per procedure and reliable supply, with procurement teams weighing all three together. Surgeons favour products that fit existing workflows in cardiovascular and general surgery, while purchasing departments push for volume discounts and stock guarantees. A local distributor with trained reps and quick restocking often decides the final selection.

Netherlands Medical Hemostatic Agents Market Share & Segment Analysis

Regional Growth Comparison - Medical Hemostatic Agents Market

RegionCAGR (2019-2033)
Asia Pacific (fastest growing)0.27%
North America-0.11%
Europe-0.18%
Middle East & Africa-0.51%
Latin America-0.64%
Source: Market Research Update, Primary InterviewsMarket Research Update

Netherlands Medical Hemostatic Agents Market By Product Type 2019-2033 (USD Million)

By Product Type201920202021202220232024202520262027202820292030203120322033
Thrombin-Based20.9222.3023.7625.3327.0028.7730.6732.6934.8437.1339.5742.1844.9547.9151.06
Fibrin Sealants10.4611.1511.8812.6613.5014.3915.3316.3417.4218.5719.7921.0922.4823.9625.53
ORC6.977.437.928.449.009.5910.2210.9011.6112.3813.1914.0614.9815.9717.02
Combination Agents5.235.575.946.336.757.197.678.178.719.289.8910.5411.2411.9812.77
Total43.5846.4549.5152.7756.2459.9463.8968.1072.5877.3682.4587.8793.6599.81106.38
Source: Market Research Update, Primary InterviewsMarket Research Update

Netherlands Medical Hemostatic Agents Market By Application 2019-2033 (USD Million)

By Application201920202021202220232024202520262027202820292030203120322033
Cardiovascular20.9222.3023.7625.3327.0028.7730.6732.6934.8437.1339.5742.1844.9547.9151.06
General Surgery10.4611.1511.8812.6613.5014.3915.3316.3417.4218.5719.7921.0922.4823.9625.53
Trauma6.977.437.928.449.009.5910.2210.9011.6112.3813.1914.0614.9815.9717.02
Neurosurgery5.235.575.946.336.757.197.678.178.719.289.8910.5411.2411.9812.77
Total43.5846.4549.5152.7756.2459.9463.8968.1072.5877.3682.4587.8793.6599.81106.38
Source: Market Research Update, Primary InterviewsMarket Research Update

Netherlands Medical Hemostatic Agents Market By End-User 2019-2033 (USD Million)

By End-User201920202021202220232024202520262027202820292030203120322033
Hospitals29.0530.9733.0135.1837.5039.9642.6045.4048.3951.5754.9758.5862.4466.5570.92
ASCs14.5215.4816.5017.5918.7519.9821.2922.7024.1925.7827.4829.2931.2133.2735.46
Total43.5846.4549.5152.7756.2459.9463.8968.1072.5877.3682.4587.8793.6599.81106.38
Source: Market Research Update, Primary InterviewsMarket Research Update

Netherlands Medical Hemostatic Agents Market Report Scope

Report AttributesReport Details
Base Year2025
Historic Data2019-2024
Market Size in 2026USD 68.10 Million
Market Forecast in 2033USD 106.38 Million
Growth RateCAGR of 6.58%
Study Period2026-2033
Key Companies ProfiledEthicon (Johnson & Johnson), Baxter International Inc., C. R. Bard (Becton Dickinson), Pfizer Inc., Takeda Pharmaceutical Company Limited, Teleflex Incorporated, B. Braun Melsungen AG, Advanced Medical Solutions Group plc, Gelita Medical GmbH, Stryker Corporation, Integra LifeSciences, CryoLife Inc.
Segments Covered
  • By Product Type: Thrombin-Based, Fibrin Sealants, ORC, Combination Agents
  • By Application: Cardiovascular, General Surgery, Trauma, Neurosurgery
  • By End-User: Hospitals, ASCs
Regions CoveredNorth America, Europe, Asia Pacific, Latin America, Middle East & Africa
Source: Market Research Update, Primary InterviewsMarket Research Update

Need it tailored? Customize your report by selecting standalone sections, regional analyses, or detailed country-level insights. Contact our experts for a tailored solution at exclusive pricing.

Customize Your Research
Netherlands Medical Hemostatic Agents Market

Date: October 2026 | Base Year: 2025 | Forecast Period: 2026-2033 | Historic Period: 2019-2024

Buy Now Request Free Sample PDF

Share Chart

Single User

Our Clients